CJC-1295 / Ipamorelin
CJC-1295 and Ipamorelin are research peptides often studied together for their synergistic effects on growth hormone (GH) release.
CJC-1295 is a synthetic analog of Growth Hormone Releasing Hormone (GHRH), designed to stimulate the pituitary gland to increase GH secretion.
Ipamorelin is a selective Growth Hormone Secretagogue Receptor (GHSR) agonist that mimics ghrelin, further enhancing GH release without significantly affecting cortisol or prolactin.
Together, these peptides are investigated in research for their roles in recovery, body composition, and metabolic support.
How It Is Used in Research Settings
- CJC-1295: Extends the half-life of GHRH activity, allowing for sustained stimulation of growth hormone release.
- Ipamorelin: Selectively binds to ghrelin receptors, triggering GH release while minimizing unwanted side effects associated with older GH secretagogues.
- Synergy: When combined, CJC-1295 provides a steady baseline GH stimulation, while Ipamorelin adds pulses of GH release, mimicking natural physiology.
Proposed Uses (Research Areas)
- Muscle recovery: Studied for supporting lean muscle growth and post-exercise recovery.
- Fat metabolism: Investigated for its potential role in reducing adipose tissue through increased lipolysis.
- Sleep quality: Some research notes improved slow-wave sleep patterns associated with GH release.
- Anti-aging studies: Examined for its possible role in supporting IGF-1 levels, tissue repair, and vitality in older models.
How It Is Dosed In Research Settings
Dosing protocols vary across studies, but typical research use includes:
- CJC-1295 (with DAC): 1–2 mg injected subcutaneously once or twice weekly, due to its extended half-life.
- CJC-1295 (without DAC): 250–500 mcg injected subcutaneously once or twice daily, often paired with Ipamorelin for pulsatile GH release.
- Ipamorelin: 200–300 mcg subcutaneously, one to three times daily, sometimes combined with CJC-1295 in the same injection.
- Cycle length: Research protocols commonly last 8–12 weeks, followed by rest periods.
Important Considerations
- Regulatory status: Neither CJC-1295 nor Ipamorelin is FDA-approved as a therapy. Both are used strictly in research contexts.
- Evidence base: Most findings come from preclinical studies and small-scale human investigations. More robust clinical trials are needed.
- Safety: Reported side effects in research settings include water retention, flushing, or tingling, though generally both peptides are well tolerated. Long-term safety is not established.
Disclaimer
This information is provided for educational purposes only and is a summary of published research on CJC-1295 and Ipamorelin.
It is not intended as medical advice. These peptides are experimental, not FDA-approved, and should not be viewed as therapies for medical use.
This peptide is for research use only.